108 related articles for article (PubMed ID: 24824064)
1. Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
Guo X; Ma X; Yang Q; Xu J; Huang L; Jia J; Shan J; Liu L; Chen W; Chu H; Wei J; Zhang X; Sun H; Tang Y; You Q
Eur J Med Chem; 2014 Jun; 81():89-94. PubMed ID: 24824064
[TBL] [Abstract][Full Text] [Related]
2. Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors.
Guo X; Yang Q; Xu J; Zhang L; Chu H; Yu P; Zhu Y; Wei J; Chen W; Zhang Y; Zhang X; Sun H; Tang Y; You Q
Bioorg Med Chem; 2013 Nov; 21(21):6466-76. PubMed ID: 24071446
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
Trotter BW; Nanda KK; Kett NR; Regan CP; Lynch JJ; Stump GL; Kiss L; Wang J; Spencer RH; Kane SA; White RB; Zhang R; Anderson KD; Liverton NJ; McIntyre CJ; Beshore DC; Hartman GD; Dinsmore CJ
J Med Chem; 2006 Nov; 49(24):6954-7. PubMed ID: 17125248
[TBL] [Abstract][Full Text] [Related]
4. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
Guo X; Chen W; Sun H; You Q
Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors.
Zhao L; Yang Q; Tang Y; You Q; Guo X
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):462-471. PubMed ID: 35012386
[TBL] [Abstract][Full Text] [Related]
6. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
[TBL] [Abstract][Full Text] [Related]
7. Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology.
Bilodeau MT; Trotter BW
Curr Top Med Chem; 2009; 9(5):436-51. PubMed ID: 19519460
[TBL] [Abstract][Full Text] [Related]
8. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.
Blass BE; Fensome A; Trybulski E; Magolda R; Gardell SJ; Liu K; Samuel M; Feingold I; Huselton C; Jackson CM; Djandjighian L; Ho D; Hennan J; Janusz JM
J Med Chem; 2009 Nov; 52(21):6531-4. PubMed ID: 19888755
[TBL] [Abstract][Full Text] [Related]
9. Discovery of aroyl piperazine derivatives as IKr & IKs dual inhibitors for cardiac arrhythmia treatment.
Guo X; Sun H; Du L; Huang L; Xu J; Zhu Y; Yu P; Zhang X; Tang Y; You Q
Med Chem; 2014; 10(5):497-505. PubMed ID: 24286394
[TBL] [Abstract][Full Text] [Related]
10. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
Johnson JA; Xu N; Jeon Y; Finlay HJ; Kover A; Conder ML; Sun H; Li D; Levesque P; Hsueh MM; Harper TW; Wexler RR; Lloyd J
Bioorg Med Chem Lett; 2014 Jul; 24(14):3018-22. PubMed ID: 24881565
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
[TBL] [Abstract][Full Text] [Related]
13. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
[TBL] [Abstract][Full Text] [Related]
14. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
[TBL] [Abstract][Full Text] [Related]
16. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
Kiper AK; Rinné S; Rolfes C; Ramírez D; Seebohm G; Netter MF; González W; Decher N
Pflugers Arch; 2015 May; 467(5):1081-90. PubMed ID: 25511502
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of voltage-gated potassium channel Kv1.5--impact on cardiac excitability.
Wettwer E; Terlau H
Curr Opin Pharmacol; 2014 Apr; 15():115-21. PubMed ID: 24632326
[TBL] [Abstract][Full Text] [Related]
18. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.
Lloyd J; Finlay HJ; Vacarro W; Hyunh T; Kover A; Bhandaru R; Yan L; Atwal K; Conder ML; Jenkins-West T; Shi H; Huang C; Li D; Sun H; Levesque P
Bioorg Med Chem Lett; 2010 Feb; 20(4):1436-9. PubMed ID: 20097068
[TBL] [Abstract][Full Text] [Related]
19. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
[TBL] [Abstract][Full Text] [Related]
20. Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach.
Kajanus J; Jacobson I; Åstrand A; Olsson RI; Gran U; Björe A; Fjellström O; Davidsson Ö; Emtenäs H; Dahlén A; Löfberg B; Yuan ZQ; Sundell J; Cassel J; Gyll J; Iliefski T; Högberg Å; Lindhardt E; Malmberg J
Bioorg Med Chem Lett; 2016 Apr; 26(8):2023-9. PubMed ID: 26965854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
